Evaluation of Trigger Tool Methodology Related to Adverse Drug Events in Hospitalized Patients

Purpose: To determine why an inpatient has had one of the following occurrences in the electronic health record due to an adverse drug event (ADE): international normalized ratio (INR) > 6, plasma blood glucose ≤ 50 mg/dL, or naloxone administration use. Utilizing the Institute for Healthcare Imp...

Full description

Bibliographic Details
Main Authors: Sara Kolc Brown, Jacob Peterson, Shayne Harris Schiedel, Kari Vavra Janes
Format: Article
Language:English
Published: Patient Safety Authority 2019-12-01
Series:Patient Safety
Subjects:
Online Access:https://patientsafetyj.com/index.php/patientsaf/article/view/155
_version_ 1797718055773536256
author Sara Kolc Brown
Jacob Peterson
Shayne Harris Schiedel
Kari Vavra Janes
author_facet Sara Kolc Brown
Jacob Peterson
Shayne Harris Schiedel
Kari Vavra Janes
author_sort Sara Kolc Brown
collection DOAJ
description Purpose: To determine why an inpatient has had one of the following occurrences in the electronic health record due to an adverse drug event (ADE): international normalized ratio (INR) > 6, plasma blood glucose ≤ 50 mg/dL, or naloxone administration use. Utilizing the Institute for Healthcare Improvement (IHI) Global Trigger Tool, the information gathered will be used to determine how to prevent these events from occurring in the future. Summary: The positive predictive value (PPV) for elevated INR was 35% (confidence interval [CI] 21–53%), hypoglycemia was 70.4% (CI 62–78%), and 53% for naloxone administration (CI 45–60%). Drug interactions were the most common factor that may have contributed to an ele-vated INR, with a mean INR of 7.9. Basal insu-lin monotherapy, recent diet changes, decreases in renal function, and iscontinuation/tapering of corticosteroids were all observed to be contributing factors to hypoglycemia events. The mean trigger glucose level was 42.98 mg/dL. Dose range order sets, high morphine mil-ligram equivalents (MME), and decreased renal func-tion may have contributed to naloxone administra-tion. Polypharmacy was attributed to some of these adverse events, with the average inpatient MME of 100.5 mg. Conclusion: The use of trigger tool methodology was useful for identifying ADEs related to hypoglycemia with insulin, moderately useful for naloxone administration, and least successful for elevated INR with warfarin. The ADEs that were identified revealed a wide variety of contributing factors that can be used as areas of interest when creating new policies and procedures to reduce ADEs in the future.
first_indexed 2024-03-12T08:45:26Z
format Article
id doaj.art-05bf63c975f14b6ab648d09064c768ef
institution Directory Open Access Journal
issn 2641-4716
language English
last_indexed 2024-03-12T08:45:26Z
publishDate 2019-12-01
publisher Patient Safety Authority
record_format Article
series Patient Safety
spelling doaj.art-05bf63c975f14b6ab648d09064c768ef2023-09-02T16:26:28ZengPatient Safety AuthorityPatient Safety2641-47162019-12-011210.33940/med/2019.12.2Evaluation of Trigger Tool Methodology Related to Adverse Drug Events in Hospitalized PatientsSara Kolc Brown0Jacob Peterson1Shayne Harris Schiedel2Kari Vavra Janes 3Meijer PharmacySpectrum HealthMeijer PharmacySpectrum Health, Ferris State University Purpose: To determine why an inpatient has had one of the following occurrences in the electronic health record due to an adverse drug event (ADE): international normalized ratio (INR) > 6, plasma blood glucose ≤ 50 mg/dL, or naloxone administration use. Utilizing the Institute for Healthcare Improvement (IHI) Global Trigger Tool, the information gathered will be used to determine how to prevent these events from occurring in the future. Summary: The positive predictive value (PPV) for elevated INR was 35% (confidence interval [CI] 21–53%), hypoglycemia was 70.4% (CI 62–78%), and 53% for naloxone administration (CI 45–60%). Drug interactions were the most common factor that may have contributed to an ele-vated INR, with a mean INR of 7.9. Basal insu-lin monotherapy, recent diet changes, decreases in renal function, and iscontinuation/tapering of corticosteroids were all observed to be contributing factors to hypoglycemia events. The mean trigger glucose level was 42.98 mg/dL. Dose range order sets, high morphine mil-ligram equivalents (MME), and decreased renal func-tion may have contributed to naloxone administra-tion. Polypharmacy was attributed to some of these adverse events, with the average inpatient MME of 100.5 mg. Conclusion: The use of trigger tool methodology was useful for identifying ADEs related to hypoglycemia with insulin, moderately useful for naloxone administration, and least successful for elevated INR with warfarin. The ADEs that were identified revealed a wide variety of contributing factors that can be used as areas of interest when creating new policies and procedures to reduce ADEs in the future.https://patientsafetyj.com/index.php/patientsaf/article/view/155global, trigger, tool, naloxone, INR, hypoglycemia
spellingShingle Sara Kolc Brown
Jacob Peterson
Shayne Harris Schiedel
Kari Vavra Janes
Evaluation of Trigger Tool Methodology Related to Adverse Drug Events in Hospitalized Patients
Patient Safety
global, trigger, tool, naloxone, INR, hypoglycemia
title Evaluation of Trigger Tool Methodology Related to Adverse Drug Events in Hospitalized Patients
title_full Evaluation of Trigger Tool Methodology Related to Adverse Drug Events in Hospitalized Patients
title_fullStr Evaluation of Trigger Tool Methodology Related to Adverse Drug Events in Hospitalized Patients
title_full_unstemmed Evaluation of Trigger Tool Methodology Related to Adverse Drug Events in Hospitalized Patients
title_short Evaluation of Trigger Tool Methodology Related to Adverse Drug Events in Hospitalized Patients
title_sort evaluation of trigger tool methodology related to adverse drug events in hospitalized patients
topic global, trigger, tool, naloxone, INR, hypoglycemia
url https://patientsafetyj.com/index.php/patientsaf/article/view/155
work_keys_str_mv AT sarakolcbrown evaluationoftriggertoolmethodologyrelatedtoadversedrugeventsinhospitalizedpatients
AT jacobpeterson evaluationoftriggertoolmethodologyrelatedtoadversedrugeventsinhospitalizedpatients
AT shayneharrisschiedel evaluationoftriggertoolmethodologyrelatedtoadversedrugeventsinhospitalizedpatients
AT karivavrajanes evaluationoftriggertoolmethodologyrelatedtoadversedrugeventsinhospitalizedpatients